This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Grant, S. Articles by Gewirtz, D. A. Search for Related Content PubMed PubMed Citation Articles by Grant, S. Articles by Gewirtz, D. A.

Potentiation of the Activity of 1-ß-D-Arabinofuranosylcytosine by the Protein Kinase C Activator Bryostatin 1 in HL-60 Cells: Association with Enhanced Fragmentation of Mature DNA¹

Departments of Medicine [S. G., W. D. J., P. S. S., A. J. T., R. S. T., H. J. W., D. A. G.], Pharmacology and Toxicology [S. G., D. A. G.], and Radiation Oncology [P-S. L.], Medical College of Virginia, Richmond, Virginia 23298, and the Cancer Research Institute [G. R. P.], Arizona State University, Tempe, Arizona 85287

We have examined the interaction between 1-ß-D-arabinofuranosylcytosine (ara-C) and the macrocyclic lactone protein kinase C activator bryostatin 1 in the human promyelocytic leukemia cell line HL-60. Preexposure of cells to 10 nM bryostatin 1 for 24 h, followed by an additional 24-h incubation with 10 µM ara-C, resulted in greater than additive inhibitory effects toward clonogenic HL-60 cells. In a series of alkaline elution assays, cells preincubated with bryostatin 1 and prelabeled with [³H]thymidine exhibited a significant increase in DNA fragmentation following exposure to ara-C in comparison to cells exposed to ara-C alone. This increase in DNA damage was apparent at both neutral and alkaline pH and was not protein associated. In contrast, studies using cells pulse-labeled with [³H]thymidine immediately before analysis suggested that bryostatin 1 pretreatment did not increase the ability of ara-C to interfere with DNA replicative intermediates. Additional studies demonstrated that the increase in DNA fragmentation induced by bryostatin 1 and ara-C preceded both loss of cell membrane integrity (as determined by trypan blue exclusion) as well as depletion of intracellular ATP and NAD pools. Furthermore, the enhanced inhibitory effects of bryostatin 1 and ara-C toward clonogenic HL-60 cells did not appear to result from the induction of cellular differentiation. Finally, agarose gel electrophoresis of DNA obtained from cells exposed to both bryostatin 1 and ara-C revealed a pattern of integer multiples of 180- to 200-base pair fragments commonly associated with endonucleolytic cleavage; the extent of this fragmentation was considerably greater than that observed in cells exposed to ara-C alone. Taken together, these findings suggest that exposure of HL-60 cells to bryostatin 1 renders them more susceptible to ara-C-related DNA damage and that this phenomenon contributes to the cytotoxic effects of this drug combination. They also raise the possibility that bryostatin 1, perhaps through modulation of intracellular signaling events in leukemic cells, has the capacity to potentiate ara-C-related apoptosis or programmed cell death.

¹ This work was supported by Grant CH-523 from the American Cancer Society (S. G.) and Cancer Center Support Core Grant CA-16059 from the National Cancer Institute, by the Medical College of Virginia Grants-in-Aid Program and A. D. Williams Foundation, the Fannie E. Rippel Foundation, the Robert B. Dalton Endowment Fund, the Thomas F. Jeffries and Kate Miller Memorial Trust, and the Bone Marrow Transplantation Core Research Laboratory of the Medical College of Virginia; G. R. P. is a recipient of Outstanding Investigator Award CA 44344-03A1; and W. D. J. is recipient of a Cancer Biology Fellowship supported by USPHS Training Grant CA-09564-05. Portions of this material were presented in preliminary form at the 82nd Meeting of the American Association for Cancer Research, Inc.

² To whom requests for reprints should be addressed.

Received 5/21/92. Accepted 9/ 9/92.

This article has been cited by other articles:

				J.-P. Truman, N. Gueven, M. Lavin, S. Leibel, R. Kolesnick, Z. Fuks, and A. Haimovitz-Friedman Down-regulation of ATM Protein Sensitizes Human Prostate Cancer Cells to Radiation-induced Apoptosis J. Biol. Chem., June 17, 2005; 280(24): 23262 - 23272. [Abstract] [Full Text] [PDF]

				S. Wang, Z. Wang, P. Dent, and S. Grant Induction of tumor necrosis factor by bryostatin 1 is involved in synergistic interactions with paclitaxel in human myeloid leukemia cells Blood, May 1, 2003; 101(9): 3648 - 3657. [Abstract] [Full Text] [PDF]

				L. Cartee, S. C. Maggio, R. Smith, H. M. Sankala, P. Dent, and S. Grant Protein Kinase C-dependent Activation of the Tumor Necrosis Factor Receptor-mediated Extrinsic Cell Death Pathway Underlies Enhanced Apoptosis in Human Myeloid Leukemia Cells Exposed to Bryostatin 1 and Flavopiridol Mol. Cancer Ther., January 1, 2003; 2(1): 83 - 93. [Abstract] [Full Text] [PDF]

				W. H. Matsui, D. E. Gladstone, M. S. Vala, J. P. Barber, R. A. Brodsky, B. D. Smith, and R. J. Jones The Role of Growth Factors in the Activity of Pharmacological Differentiation Agents Cell Growth Differ., June 1, 2002; 13(6): 275 - 283. [Abstract] [Full Text] [PDF]

				L. Cartee, R. Smith, Y. Dai, M. Rahmani, R. Rosato, J. Almenara, P. Dent, and S. Grant Synergistic Induction of Apoptosis in Human Myeloid Leukemia Cells by Phorbol 12-Myristate 13-Acetate and Flavopiridol Proceeds via Activation of Both the Intrinsic and Tumor Necrosis Factor-Mediated Extrinsic Cell Death Pathways Mol. Pharmacol., June 1, 2002; 61(6): 1313 - 1321. [Abstract] [Full Text] [PDF]

				Z. Wang, S. Wang, Y. Dai, and S. Grant Bryostatin 1 Increases 1-beta -D-Arabinofuranosylcytosine-Induced Cytochrome c Release and Apoptosis in Human Leukemia Cells Ectopically Expressing Bcl-xL J. Pharmacol. Exp. Ther., May 1, 2002; 301(2): 568 - 577. [Abstract] [Full Text] [PDF]

				J. A. Vrana and S. Grant Synergistic induction of apoptosis in human leukemia cells (U937) exposed to bryostatin 1 and the proteasome inhibitor lactacystin involves dysregulation of the PKC/MAPK cascade Blood, April 1, 2001; 97(7): 2105 - 2114. [Abstract] [Full Text] [PDF]

				L. Cartee, Z. Wang, R. H. Decker, S. P. Chellappan, G. Fusaro, K. G. Hirsch, H. M. Sankala, P. Dent, and S. Grant The Cyclin-dependent Kinase Inhibitor (CDKI) Flavopiridol Disrupts Phorbol 12-Myristate 13-Acetate-induced Differentiation and CDKI Expression while Enhancing Apoptosis in Human Myeloid Leukemia Cells Cancer Res., March 1, 2001; 61(6): 2583 - 2591. [Abstract] [Full Text]

				Y. Ito, P. Pandey, A. Place, M. B. Sporn, G. W. Gribble, T. Honda, S. Kharbanda, and D. Kufe The Novel Triterpenoid 2-Cyano-3,12-dioxoolean-1,9-dien-28-oic Acid Induces Apoptosis of Human Myeloid Leukemia Cells by a Caspase-8-dependent Mechanism Cell Growth Differ., May 1, 2000; 11(5): 261 - 267. [Abstract] [Full Text]

				S. Weitman, A.-M. Langevin, R. L. Berkow, P. J. Thomas, C. A. Hurwitz, A. S. Kraft, R. L. Dubowy, D. L. Smith, and M. Bernstein A Phase I Trial of Bryostatin-1 in Children with Refractory Solid Tumors: A Pediatric Oncology Group Study Clin. Cancer Res., September 1, 1999; 5(9): 2344 - 2348. [Abstract] [Full Text] [PDF]

				Q. P. Dou, T. F. McGuire, Y. Peng, and B. An Proteasome Inhibition Leads to Significant Reduction of Bcr-Abl Expression and Subsequent Induction of Apoptosis in K562 Human Chronic Myelogenous Leukemia Cells J. Pharmacol. Exp. Ther., May 1, 1999; 289(2): 781 - 790. [Abstract] [Full Text]

				B. W. Parker, G. Kaur, W. Nieves-Neira, M. Taimi, G. Kohlhagen, T. Shimizu, M. D. Losiewicz, Y. Pommier, E. A. Sausville, and A. M. Senderowicz Early Induction of Apoptosis in Hematopoietic Cell Lines After Exposure to Flavopiridol Blood, January 15, 1998; 91(2): 458 - 465. [Abstract] [Full Text] [PDF]

				T Goldkorn, N Balaban, M Shannon, V Chea, K Matsukuma, D Gilchrist, H Wang, and C Chan H2O2 acts on cellular membranes to generate ceramide signaling and initiate apoptosis in tracheobronchial epithelial cells J. Cell Sci., January 11, 1998; 111(21): 3209 - 3220. [Abstract] [PDF]

				S. Wang, J. A. Vrana, T. M. Bartimole, A. J. Freemerman, W. D. Jarvis, L. B. Kramer, G. Krystal, P. Dent, and S. Grant Agents that Down-Regulate or Inhibit Protein Kinase C Circumvent Resistance to 1-beta -D-Arabinofuranosylcytosine-Induced Apoptosis in Human Leukemia Cells that Overexpress Bcl-2 Mol. Pharmacol., December 1, 1997; 52(6): 1000 - 1009. [Abstract] [Full Text]